Prognostic Value of CDKN2A Copy Number Deletion in Patients with Diffuse Large B-Cell Lymphoma.
10.19746/j.cnki.issn.1009-2137.2025.02.011
- Author:
Wei-Yuan MA
1
;
Le-Tian SHAO
2
;
Wen-Xin TIAN
3
;
Sha LIU
3
;
Yan LI
3
Author Information
1. Shihezi University School of Medicine, Shihezi 832000, Xinjiang Uygur Autonomous Region, China.
2. Xinjiang Medical University； Urumqi 830000, Xinjiang Uygur Autonomous Region, China.
3. Department of Hematology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830000, Xinjiang Uygur Autonomous Region, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Lymphoma, Large B-Cell, Diffuse/genetics*;
Prognosis;
Cyclin-Dependent Kinase Inhibitor p16/genetics*;
DNA Copy Number Variations;
Female;
Male;
Middle Aged;
Gene Deletion;
Adult;
Aged
- From:
Journal of Experimental Hematology
2025;33(2):379-386
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the relationship between CDKN2A copy number deletion and clinical features of patients with diffuse large B-cell lymphoma (DLBCL) and its prognostic value.
METHODS:155 newly diagnosed DLBCL patients with complete clinical data in the Department of Hematology of People's Hospital of Xinjiang Uygur Autonomous Region from March 2009 to March 2022 were included, formalin-fixed paraffin-embedded tumor tissues were obtained and DNA was extracted from them, and next-generation sequencing technology was applied to target sequencing including 475 lymphoma-related genes, the relationship between CDKN2A copy number deletion and clinical features, high-frequency mutated genes and overall survival (OS) of DLBCL patients were analyzed.
RESULTS:CDKN2A copy number deletion was present in 12.9% (20/155) of 155 DLBCL patients, grouped according to the presence or absence of copy number deletion of CDKN2A, and a higher proportion of patients with IPI≥3 were found in the CDKN2A copy number deletion group compared to the group with no CDKN2A copy number deletion (80% vs 51.5%, P =0.015) and were more likely to have bulky disease (20% vs 5.2%, P =0.037). Survival analysis showed that the 5-year OS of patients in the CDKN2A copy number deletion group was significantly lower than that of the non-deletion group (51.3% vs 69.2%, P =0.047). Multivariate Cox analysis showed that IPI score≥3 (P =0.007), TP53 mutation (P =0.009), and CDKN2A copy number deletion (P =0.04) were independent risk factors affecting the OS of DLBCL patients.
CONCLUSION:CDKN2A copy number deletion is an independent risk factor for OS in DLBCL, and accurate identification of CDKN2A copy number deletion can predict the prognosis of DLBCL patients.
